Trending at Lumira Ventures

Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent, Treosulfan. Which pioneers Hematopoietic Stem Cell transplantation in the US.

Abi Kumar Portfolio News, Medexus Pharmaceuticals

TORONTO and CHICAGO and MONTREAL and WEDEL, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (“Medexus”) (TSXV: MDP) (OTCQX: MEDXF)(Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (“Medexus Pharma” …

Medexus Pharmaceuticals Launches New Dosage for Treatment of Rheumatoid Arthritis, Psoriasis & Psoriatic Arthritis in Canada

Jennifer Schram Portfolio News, Medexus Pharmaceuticals

MONTREAL, May 7, 2019 — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), today announced the launch of a new Metoject® Subcutaneous 15mg dose in Canada. Metoject Subcutaneous is a pre-filled syringe of methotrexate with a pre-attached subcutaneous …